ACTRN12618000656235已完成未知
Identifying the efficacy of the plant-origin flavonoid rutin and targeting amylin to restore insulin secretion and prevent progression to diabetes in prediabetic participants
niversity of Auckland Research Office0 个研究点目标入组 87 人开始时间: 2018年4月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 87
研究概览
简要总结
Stats analysis are underway, results will be updated when ready.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Aged between 18-65 years
- •BMI between 23-35kg/m2
- •Fasting plasma glucose (FPG) greater than or equal to 5.6 – 6.9 mmol/L
- •FINDRISC greather than or equal to 12
- •Otherwise healthy by self-report
排除标准
- •Type 2 or type 1 diabetes
- •Other significant disease including cardiovascular disease, pancreatic disease or cancer; or digestive disease including inflammatory bowel syndrome/disease (IBS/D), ulcerative colitis (UC), Crohn's disease
- •Medications controlling glycaemia
- •Current use of rutin or quercetin supplements
- •Recent body weight loss/gain >10% within previous 3 months or taking part in an active diet program; or current medications for weight loss
- •Dislike or unwilling to consume food items included in the study, or hypersensitivities or allergies to these foods, i.e. rutin allergy, lactose intolerant, does not consume yogurt
- •Pregnant or breastfeeding women
- •Unwilling/unable to comply with study protocol
- •Concurrent participation in other clinical studies, or such participation within the last 3 months
研究者
相似试验
已完成
不适用
Matrix on Fruit Constituent BioavailabilityHealthy Non-smokerNCT01908634Clinical Nutrition Research Center, Illinois Institute of Technology10
Unknown
2 期
Plant-based Mince vs Beef Mince: Does One Make You Feel Fuller for Longer?Healthy ParticipantsNCT04950595Commonwealth Scientific and Industrial Research Organisation, Australia28
进行中（未招募）
1 期
Estudio pivotal para determinar la eficacia y seguridad de AP23573 administrado como tratamiento de mantenimiento a pacientes con sarcoma metastásico óseo o de partes blandas.Patients who have benefited from cytotoxic chemotherapy. Patients will have either metastatic soft-tissue or bone sarcoma, with histological category (soft-tissue or bone) as one of the baseline stratification factors. Impotantly, in this trial, bone sarcoma patients must have visceral metastatic disease (e.g., metastatic to lung or liver), or have achieved response of visceral metasrasis.MedDRA version: 9.1Level: LLTClassification code 10006008Term: Bone sarcoma NOSMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasEUCTR2007-003462-18-ESARIAD Pharmaceuticals, Inc.675
已完成
2 期
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 ExpressionOvarian Epithelial CarcinomaNCT01536743Jonsson Comprehensive Cancer Center26
已完成
2 期
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mgAdvanced Breast CancerMetastatic Breast CancerNCT00305448AstraZeneca143